Quarterly report · Q1
2784.TEDINET S100RN02
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥709.1bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥657.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥5.8bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥6.4bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.7bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥6.4bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.0bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.1bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥2.2bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥1.39T | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.33T | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥909.2bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥479.9bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥475.5bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥169.4bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥20.15 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.5 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.8% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥8.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥8.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | ¥129m |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥631.6bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥626.8bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥4.8bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥5.3bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥12.3bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥8.8bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3.5bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥442m |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥8.9bn |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥8.9bn |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥82m |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥64.6bn |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥64.5bn |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥153m |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥770m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥717.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥709.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥8.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥5.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥7.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥7.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | ¥82m |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥585.4bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥580.9bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥11.0bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.9bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.1bn |
| jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥207m |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥8.8bn |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥8.8bn |
| jpcrp040300-q1r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥92m |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥59.6bn |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥59.5bn |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥142m |
| jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥448m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥664.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥657.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥7.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 371
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -7745000000 | JPY |
| Net sales | Prior1YTDDuration | 657122000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 2443000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 448000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember | 207000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | -92000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 3006000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | 82000000 | JPY |
| Operating income | Prior1YTDDuration | 3088000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 626811000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 64473000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember | 8840000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 8931000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 709056000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 709056000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 4783000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 153000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember | 3486000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 8423000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -8423000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 631595000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 64627000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember | 12326000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 8931000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 717480000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -8423000000 | JPY |
| Net sales | CurrentYTDDuration | 709056000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 5295000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 770000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember | -442000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 82000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 5706000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | 129000000 | JPY |
| Operating income | CurrentYTDDuration | 5835000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-08-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第21期第１四半期(自 2023年４月１日 至 2023年６月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)アルフレッサ ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Alfresa Holdings Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 荒川 隆治 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番３号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5219-5100 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)代表取締役 副社長社長補佐 総務・財務企画・コーポレートコミュニケーション・コンプライアンス担当岸田 誠一 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番３号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5219-5100 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |